Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 9/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 9/20 | 0.37 |
| ▸ | ITGB7 | P26010 | 6/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | FLT1 | P17948 | 1/20 | 0.30 |
| ▸ | FLT4 | P35916 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
| ▸ | ITGAV | P06756 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4196939 | 0.95 | ITGB1 (0.36) | ITGB1ITGA4ITGB7BRAFALDH1A1 | |
| Hydrochloric Acid SCHEMBL4192130 | 0.93 | ITGB1 (0.37) | ITGB1ITGA4ITGB7BRAFALDH1A1 | |
| SCHEMBL4204707 | 0.91 | ITGB1 (0.36) | ITGB1ITGA4ITGB7BRAF | |
| SCHEMBL4203924 | 0.89 | ITGB1 (0.35) | ITGB1ITGA4ITGB7ALDH1A1 | |
| SCHEMBL4196190 | 0.89 | ITGB1 (0.36) | ITGB1ITGA4ITGB7BRAF | |
| SCHEMBL2769475 | 0.87 | ITGB1 (0.38) | ITGB1ITGA4ITGB7BRAFALDH1A1 | |
| SCHEMBL4203929 | 0.85 | ITGB1 (0.35) | ITGB1ITGA4ITGB7BRAF | |
| SCHEMBL4195563 | 0.85 | ITGB1 (0.35) | ITGB1ITGA4ITGB7BRAFITGAV | |
| SCHEMBL6038349 | 0.84 | ITGB1 (0.38) | ITGB1ITGA4ITGB7ALDH1A1KDM4E | |
| SCHEMBL2808033 | 0.83 | ITGB1 (0.35) | ITGB1ITGA4ITGB7BRAFALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8269009-B2 | Methods and compositions for treating liquid tumors | ELAN PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20090312353-A1 | Methods and compositions for treating liquid tumors | ELAN PHARMACEUTICALS, INC. | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312353-A1 | Methods and compositions for treating liquid tumors | ITGB4, ITGA4, ITGB3 | ITGB1 4/4885ITGA4 2/4885ITGB7 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.